Epacadostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Epacadostat
Accession Number
DB11717
Type
Small Molecule
Groups
Investigational
Description

Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
INCB-024360
Categories
Not Available
UNII
71596A9R13
CAS number
1204669-58-8
Weight
Average: 438.23
Monoisotopic: 436.991714
Chemical Formula
C11H13BrFN7O4S
InChI Key
FBKMWOJEPMPVTQ-UHFFFAOYSA-N
InChI
InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
IUPAC Name
(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole-3-carboximidamide
SMILES
NS(=O)(=O)NCCNC1=NON=C1\C(NC1=CC(Br)=C(F)C=C1)=N\O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
91826917
PubChem Substance
347828080
ChemSpider
34448418
BindingDB
50126143
ChEMBL
CHEMBL3545369
HET
BBJ
Wikipedia
Epacadostat
PDB Entries
5wn8

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentStage III Fallopian Tube Cancer / Stage III Fallopian Tube Cancer AJCC v7 / Stage III Ovarian Cancer / Stage III Ovarian Cancer AJCC v6 and v7 / Stage III Primary Peritoneal Cancer / Stage III Primary Peritoneal Cancer AJCC v7 / Stage IIIA Fallopian Tube Cancer / Stage IIIA Fallopian Tube Cancer AJCC v7 / Stage IIIA Ovarian Cancer / Stage IIIA Ovarian Cancer AJCC v6 and v7 / Stage IIIA Primary Peritoneal Cancer / Stage IIIA Primary Peritoneal Cancer AJCC v7 / Stage IIIB Fallopian Tube Cancer / Stage IIIB Fallopian Tube Cancer AJCC v7 / Stage IIIB Ovarian Cancer / Stage IIIB Ovarian Cancer AJCC v6 and v7 / Stage IIIB Primary Peritoneal Cancer / Stage IIIB Primary Peritoneal Cancer AJCC v7 / Stage IIIC Fallopian Tube Cancer / Stage IIIC Fallopian Tube Cancer AJCC v7 / Stage IIIC Ovarian Cancer / Stage IIIC Ovarian Cancer AJCC v6 and v7 / Stage IIIC Primary Peritoneal Cancer / Stage IIIC Primary Peritoneal Cancer AJCC v7 / Stage IV Fallopian Tube Cancer / Stage IV Fallopian Tube Cancer AJCC v6 and v7 / Stage IV Ovarian Cancer / Stage IV Ovarian Cancer AJCC v6 and v7 / Stage IV Primary Peritoneal Cancer / Stage IV Primary Peritoneal Cancer AJCC v71
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Tumors, Solid1
1Not Yet RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentAdvanced Solid Tumors / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasms1
1RecruitingTreatmentUnresectable or Metastatic Solid Tumors1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / NSCLC (Non-small Cell Lung Carcinoma) / Transitional Cell Carcinoma / UC (Urothelial Cancer)1
1WithdrawnTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1WithdrawnTreatmentLeukemia Acute Myeloid Leukemia (AML) / Relapses1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Advanced Solid Tumors / Cancer, Advanced / Metastatic Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Metastatic Cancers / Metastatic Malignancy1
1, 2Active Not RecruitingTreatmentAdvanced or Metastatic Solid Tumors / Tumors, Solid1
1, 2Active Not RecruitingTreatmentB Cell NHL Including DLBCL / B-Cell Malignancies / Cancer of the Ovary / Carcinoma, Squamous Cell of Head and Neck / Colorectal Cancer (CRC) / CRC (Colorectal Cancer) / Glioblastomas / Head and Neck Carcinoma / HL / HNSCC (Head and Neck Squamous Cell Cancer / Hodgkin Lymphona (B-cell Malignancies) / I/O naïve Melanoma (MEL) / I/O Refractory MEL / I/O Relapsed MEL / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Malignant Lymphomas / Melanoma / Neoplasms, Colorectal / Neoplasms, Ovarian1
1, 2Active Not RecruitingTreatmentPlatinum-resistant Fallopian Cancer / Platinum-resistant Ovarian Cancer / Platinum-resistant Peritoneal Cancer1
1, 2Not Yet RecruitingTreatmentGlioblastomas / Gliomas1
1, 2Not Yet RecruitingTreatmentRectal Carcinoma1
1, 2RecruitingTreatmentAdenocarcinoma (PDAC) / Advanced or Metastatic Colorectal Cancer (CRC) / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor / Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor / Advanced or Metastatic Solid Tumors / Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Advanced or Metastatic Urothelial Carcinoma (UC) / Colorectal Cancer (CRC) / Head and Neck Carcinoma / Lung Cancers / Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) / Pancreatic Ductal Adenocarcinoma (PDAC) / Tumors, Solid / UC (Urothelial Cancer)1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Malignant Lymphomas1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Metastatic Hormone Refractory Prostate Cancer / Prostate Cancer / Prostate Neoplasms / Tumors, Solid1
1, 2RecruitingTreatmentAdvanced or Metastatic Solid Tumors / Tumors, Solid1
1, 2RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma1
1, 2RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Peritoneal Cancer / Recurrent, Epithelial Ovarian Cancer1
1, 2WithdrawnTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentLung Cancers / Metastatic Non-Small Cell Lung Cancer2
2CompletedTreatmentMucosal Melanoma / Recurrent Melanoma / Recurrent Uveal Melanoma / Stage IIIA Skin Melanoma / Stage IIIA Uveal Melanoma / Stage IIIB Skin Melanoma / Stage IIIB Uveal Melanoma / Stage IIIC Skin Melanoma / Stage IIIC Uveal Melanoma / Stage IV Skin Melanoma / Stage IV Uveal Melanoma1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Stage IV Esophageal Cancer AJCC v7 / Stage IV Gastric Cancer AJCC v7 / Unresectable Esophageal Carcinoma1
2RecruitingTreatmentGastrointestinal Stromal Tumors1
2RecruitingTreatmentHead and Neck Carcinoma / Head and Neck Squamous Cell Carcinoma (HNSCC)1
2RecruitingTreatmentMalignant Ovarian Clear Cell Tumor / Recurrent Ovarian Carcinoma1
2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentThymic Carcinoma / Thymus Cancer / Thymus Neoplasms1
2WithdrawnTreatmentAdenocarcinoma of the Pancreas1
2WithdrawnTreatmentClinical Stage II Esophageal Adenocarcinoma AJCC v8 / Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 / Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 / Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8 / Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Clinical Stage III Esophageal Adenocarcinoma AJCC v8 / Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 / Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 / Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 / Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8 / Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v81
2WithdrawnTreatmentExtensive Stage Small Cell Lung Carcinoma1
2WithdrawnTreatmentHead and Neck Carcinoma1
2WithdrawnTreatmentRecurrent/ Metastatic Endometrial Carcinoma1
3Active Not RecruitingTreatmentAdvanced/Unresectable (Inoperable) Urothelial Cancer / Metastatic Urothelial Cancer / UC (Urothelial Cancer)1
3Active Not RecruitingTreatmentHead and Neck Carcinoma / Metastatic Head and Neck Squamous Cell Carcinoma / Recurrent Head and Neck Squamous Cell Carcinoma1
3Active Not RecruitingTreatmentLocally Advanced or Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
3Active Not RecruitingTreatmentMelanoma1
3Active Not RecruitingTreatmentRecurrent or Progressive Metastatic Urothelial Carcinoma / UC (Urothelial Cancer)1
3TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
3WithdrawnTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.419 mg/mLALOGPS
logP1.43ALOGPS
logP0.089ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area167.76 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity93.53 m3·mol-1ChemAxon
Polarizability35.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Fluorobenzenes
Alternative Parents
Secondary alkylarylamines / Bromobenzenes / Sulfuric acid diamides / Imidolactams / Aryl fluorides / Aryl bromides / Heteroaromatic compounds / Furazans / Azacyclic compounds / Amidines
show 5 more
Substituents
Bromobenzene / Fluorobenzene / Secondary aliphatic/aromatic amine / Aryl bromide / Aryl fluoride / Aryl halide / Imidolactam / Sulfuric acid diamide / Azole / Heteroaromatic compound
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:42 / Updated on November 02, 2018 07:14